

K960350

K960350

510(k) Summary
for the
theraPORT[®] Vascular Access System

APR 15 1996

GENERAL INFORMATION:

| | |
|--------------------------------|--|
| Common/Usual Names: | Implanted Subcutaneous Intravascular Catheter; Implantable Vascular Access System; Implanted Infusion Port |
| Proprietary Name: | theraPORT[®] Vascular Access System |
| Applicant: | Biocontrol Technology, Inc. 300 Indian Springs Road Indiana, PA 15701 (412)349-1811 |
| Equivalence Device Comparison: | Cook Pacemaker Corporation, VITAL-PORT [®] Vascular Access Port with Detached Catheter; Pharmacia Deltec, Inc., PORT-A-CATH [®] Implant- able Access System; and Therex, Inc., A-PORT [®] Implantable Vascular Access System. |

DEVICE DESCRIPTION:

The **theraPORT[®]** Vascular Access System is a totally implantable venous access system consisting of a detached catheter and port.

INTENDED USE:

The **theraPORT[®]** is intended for use with patients that require repeated venous access for injection or infusion therapy and/or venous blood sampling.

ALTERNATIVE DEVICES:

Alternative devices to the **theraPORT[®]** Vascular Access System are other commercially available implantable vascular venous access systems such as the Cook Pacemaker Corporation, VITAL-PORT[®] Vascular Access Port with Detached Catheter, the Pharmacia Deltec, Inc., PORT-A-CATH[®] Implantable Access System, and the Therex Corporation, A-PORT[®] Implantable Vascular Access System.

POTENTIAL ADVERSE EFFECTS:

The following adverse effects, which are normally associated with the insertion or use of any implanted device or indwelling catheter, may occur when using the **theraPORT®** Vascular Access System: air embolism, bacteremia, catheter disconnection, catheter fragmentation, cardiac arrhythmia, cardiac puncture, cardiac tamponade, catheter occlusion, catheter rupture, catheter shearing, catheter/port erosion through blood vessel/skin, catheter/port migration, drug extravasation, hematoma, hemothorax, implant rejection, infection, laceration or puncture of vessels, pneumothorax, sepsis, thromboembolism, thrombophlebitis, thrombosis.

SUMMARY OF STUDIES:

Performance Testing:

Performance testing of the **theraPORT®** Vascular Access System was conducted in accordance with the "Guidance on 510(k) Submissions for Implanted Infusion Ports," Center for Devices and Radiological Health, Office of Device Evaluation, Division of Gastroenterology/Urology and General Use Devices, Food and Drug Administration, October 1990. Catheter-to-port connection strength tests, septum puncture durability tests, port leakage integrity tests and port/catheter clearance tests were all performed.

Biocompatibility testing was not conducted since all materials, their processing, and their sterilization are identical to substantially equivalent devices.

Clinical Studies:

Clinical studies were not conducted as they were determined to be not necessary due to the similarity in design, performance, materials, function and intended use of the **theraPORT®** Vascular Access System to other commercially available systems.

CONCLUSIONS DETERMINED FROM TESTS:

The above described studies demonstrate that the **theraPORT®** Vascular Access System functions properly and is substantially equivalent to the aforementioned commercially available predicate devices. Therefore, the **theraPORT®** Vascular Access System is determined to be safe and effective for its intended use.

theraPORT® is a registered trademark of Biocontrol Technology, Inc.

A-Port® is a registered trademark of Therex, Corp.

Port-A-Cath® is a registered trademark of Pharmacia-Deltec, Inc.

Vital-Port® is a registered trademark of Cook Pacemaker Corp.